(Q43051298)

English

Evaluation of the effect of continuous infusion recombinant interleukin-2 (bioleukin) on peripheral blood leucocytes of patients with terminal malignancy

scientific article published in December 1989

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

13 November 2017

Evaluation of the effect of continuous infusion recombinant interleukin-2 (bioleukin) on peripheral blood leucocytes of patients with terminal malignancy (English)

1 reference

Europe PubMed Central

PMC publication ID

13 November 2017

author name string

Oliver RT

1

1 reference

Europe PubMed Central

PMC publication ID

13 November 2017

Crosby D

2

1 reference

Europe PubMed Central

PMC publication ID

13 November 2017

Nouri A

3

1 reference

Europe PubMed Central

PMC publication ID

13 November 2017

Scott E

4

1 reference

Europe PubMed Central

PMC publication ID

13 November 2017

Galazka A

5

1 reference

Europe PubMed Central

PMC publication ID

13 November 2017

language of work or name

0 references

publication date

1 December 1989

1 reference

Europe PubMed Central

PMC publication ID

13 November 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

13 November 2017

60

1 reference

Europe PubMed Central

PMC publication ID

13 November 2017

6

1 reference

Europe PubMed Central

PMC publication ID

13 November 2017

934-937

1 reference

Europe PubMed Central

PMC publication ID

13 November 2017

Interferons in the treatment of human cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247261

26 May 2018

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247261

26 May 2018

Preliminary clinical observations with recombinant interleukin-2 in patients with AIDS or LAS.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247261

26 May 2018

A phase I study of recombinant interleukin 2 in melanoma patients. Toxicity and clinical effects.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247261

26 May 2018

Phase 1 clinical evaluation of recombinant interleukin-2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247261

26 May 2018

Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247261

26 May 2018

In vivo activation of lymphocytes in melanoma patients receiving escalating doses of recombinant interleukin 2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247261

26 May 2018

Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247261

26 May 2018

In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247261

26 May 2018

Interleukin 2 (IL 2) administered in vivo: influence of IL 2 route and timing on T cell growth

1 reference

https://pubmed.ncbi.nlm.nih.gov/2605101

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/2605101

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/BJC.1989.393

1 reference

Europe PubMed Central

PMC publication ID

13 November 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43051298&oldid=2205768998"